WBH Advisory Inc. Has $242,000 Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

WBH Advisory Inc. trimmed its holdings in Bristol-Myers Squibb (NYSE:BMY) by 33.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,824 shares of the biopharmaceutical company’s stock after selling 2,969 shares during the quarter. WBH Advisory Inc.’s holdings in Bristol-Myers Squibb were worth $242,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Traynor Capital Management Inc. grew its position in shares of Bristol-Myers Squibb by 2.8% in the first quarter. Traynor Capital Management Inc. now owns 7,672 shares of the biopharmaceutical company’s stock valued at $416,000 after purchasing an additional 207 shares during the last quarter. Fulton Breakefield Broenniman LLC increased its position in shares of Bristol-Myers Squibb by 4.6% in the fourth quarter. Fulton Breakefield Broenniman LLC now owns 4,744 shares of the biopharmaceutical company’s stock worth $243,000 after purchasing an additional 209 shares during the period. Accurate Wealth Management LLC grew its stake in Bristol-Myers Squibb by 4.0% during the first quarter. Accurate Wealth Management LLC now owns 5,612 shares of the biopharmaceutical company’s stock worth $304,000 after buying an additional 216 shares in the last quarter. Newbridge Financial Services Group Inc. increased its holdings in Bristol-Myers Squibb by 12.8% in the 1st quarter. Newbridge Financial Services Group Inc. now owns 1,910 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 216 shares during the period. Finally, Bfsg LLC raised its position in shares of Bristol-Myers Squibb by 24.4% in the 1st quarter. Bfsg LLC now owns 1,120 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 220 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Up 0.5 %

Shares of Bristol-Myers Squibb stock traded up $0.25 during trading hours on Friday, reaching $47.10. The company’s stock had a trading volume of 3,804,003 shares, compared to its average volume of 15,900,625. The company has a debt-to-equity ratio of 2.86, a quick ratio of 0.99 and a current ratio of 1.16. The stock’s fifty day simple moving average is $42.91 and its two-hundred day simple moving average is $46.67. The company has a market capitalization of $95.48 billion, a P/E ratio of -15.11, a P/E/G ratio of 12.51 and a beta of 0.44. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $63.41.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.64 by $0.43. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The business had revenue of $12.20 billion for the quarter, compared to analysts’ expectations of $11.54 billion. During the same period last year, the business earned $1.75 EPS. The business’s revenue was up 8.7% on a year-over-year basis. On average, research analysts forecast that Bristol-Myers Squibb will post 0.77 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, August 1st. Investors of record on Friday, July 5th were issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 5.10%. The ex-dividend date of this dividend was Friday, July 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -77.42%.

Analysts Set New Price Targets

BMY has been the subject of several research analyst reports. Cantor Fitzgerald reissued a “neutral” rating and set a $45.00 target price on shares of Bristol-Myers Squibb in a research note on Monday, July 22nd. Barclays cut shares of Bristol-Myers Squibb from an “overweight” rating to an “equal weight” rating and set a $41.00 target price on the stock. in a research note on Monday, July 29th. Wells Fargo & Company increased their price target on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research note on Thursday, April 18th. StockNews.com upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 29th. Finally, Deutsche Bank Aktiengesellschaft dropped their target price on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a research report on Tuesday, July 23rd. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Bristol-Myers Squibb currently has an average rating of “Hold” and a consensus target price of $55.79.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.